LiGHT 2026

Singapore Introduces Low-Cost, Precise Cancer Blood Test

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

WebMD Ignite Ruby Transforms Healthcare Marketing...

WebMD Ignite has announced the launch of WebMD Ignite...

Mayo Clinic Study Validates AI Tool...

Researchers at Mayo Clinic have found that an artificial...

MHRA Outlines New Agenda for AI...

The United Kingdomโ€™s Medicines and Healthcare products Regulatory Agency...

Researchers at the National University of Singapore (NUS) have developed a revolutionary, inexpensive technique for cancer screening. This novel test, known as the Heatrich-BS assay, uses heated biomarkers to analyze blood samples in order to find cancer-specific signals.

The novel technique offers tissue biopsies as a promising non-invasive replacement. When compared to alternative sequencing methods, which can cost up to S$1,000 to complete, it costs about S$50 from beginning to end.

The team, which includes academics from the NUS Institute for Health Innovation & Ideas and the NUS Department of Biomedical Engineering, is currently looking into business collaborations to help commercialise their technology. The team is headed by Assistant Professor Cheow Lih Feng.

The National Cancer Centre in Singapore has tested the Heatrich-BS assay to monitor patients with colorectal cancer. The scientists discovered a strong association between the amount of cancer-specific DNA found in a patient’s blood sample and the development of their tumours over time by comparing the findings of their blood testing with CT scans that assessed the size of the patients’ tumours.

The assay might hasten upcoming academic research by enabling researchers to explore many cancer subtypes on a budget, leading to better cancer detection and treatment in the future.

Now, Asst. Prof. Cheow and his group are looking into methods to work with pharmaceutical and biotechnology firms that can assist in bringing the Heatrich-BS assay to market in order to commercialise their assessment.

Never miss a healthcare headline

Healthcare moves fast โ€“ stay on top of it with our must - read briefings.

  • The top hospital and healthcare stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments transforming global healthcare management

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media PackNow

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Latest stories

Related stories

Mayo Clinic Study Validates AI Tool DEXI for Skin Lesion Assessment

Researchers at Mayo Clinic have found that an artificial...

MHRA Outlines New Agenda for AI Medical Devices at AdvaMed

The United Kingdomโ€™s Medicines and Healthcare products Regulatory Agency...

UK Confirms Indefinite Use of CE Marked Medical Devices

The United Kingdom government has officially confirmed the indefinite...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป